Arsenic is a carcinogen that poses a significant health risk in humans. Based on evidence that arsenic has differential effects on human, rodent, normal, and transformed cells, these studies addressed the relative merits of using normal human epidermal keratinocytes (NHEK) and immortalized human (HaCaT) and mouse (HEL30) keratinocytes when examining stress-induced gene expression that may contribute to carcinogenesis. We hypothesize that redox-related gene expression is differentially modulated by arsenic in normal versus immortalized keratinocytes. To test the hypothesis, we exposed keratinocytes to sodium arsenite for 4 or 24 hr, at which time serine threonine kinase-25 (stk25) and nicotine adenine dinucleotide phosphate [nad(p)h] quinone oxidoreductase gene expression were measured. The effect of glutathione reduction on arsenite-induced cytotoxicity and gene expression in NHEK also was evaluated by addition of l-buthionine-[S,R]-sulfoximine (BSO) to culture media. Results indicate the term LC50 for arsenite is approximately 10–15 µM in NHEK and HEL30 keratinocytes and 30 µM in HaCaT keratinocytes. Compared with HaCaT and HEL30 keratinocytes, a nontoxic concentration of arsenite (2.5 µM) increases stk25 and nad(p)h quinone oxidoreductase gene expression in NHEK, an effect partially attenuated by BSO. These data indicate that NHEK and HaCaT/HEL30 keratinocytes have similar sensitivities toward arsenite-induced cytotoxicity but unique gene expression responses. They also suggest that arsenite modulates gene expression in NHEK involved in cellular signaling and other aspects of intermediary metabolism that may contribute to the carcinogenic process. Key words: arsenite, glutathione, keratinocyte, redox, toxicity.

Understanding toxicant effects on epidermal keratinocytes is critical because disturbances in keratinocyte function are responsible for the pathogenesis of many skin diseases such as psoriasis and skin cancer (1,2). Skin cancer is a common manifestation of arsenic exposure, and keratinocytes are a primary target of arsenic in vivo (3–9). Both primary and immortalized keratinocytes have been used in studies examining arsenic-induced skin cancer and epidermal toxicity. However, data derived from experiments using immortalized keratinocytes may be complicated by clonal variability, variations between passage, altered antioxidant complement, immortalization-specific gene expression, and alterations in differentiation capacity—variables not encountered to the same degree with primary keratinocytes.

Mechanisms proposed to be involved in the development of arsenic-induced cancer in skin and other tissues include altered DNA methylation (10–12), DNA repair/repllication disturbances (13,14), clastogenicity and aneuploidy (15), dysregulated cell proliferation (10,16), and generation of oxidative stress (17,18). Arsenic-induced oxidative stress or redox disturbance (17,19–21) contributes to DNA damage (22–24), chromosomal aberrations (25), and protein expression alterations (22,26). However, its role in arsenic carcinogenesis is not completely understood. Glutathione (GSH)-dependent enzymes are not significantly sensitive to arsenicals (27), but these enzymes play a significant role in attenuating the damaging effects of oxidative stress. It is conceivable that short- and long-term changes in GSH-dependent and stress-related mRNA/protein expression, modulated by arsenic, could abnormally affect cellular viability, phase I/II metabolism, and other GSH-mediated regulatory processes, and could be important in the development of arsenic-induced cancer.

This study was undertaken to determine the merits of using normal human epidermal keratinocytes (NHEK) and immortalized human (HaCaT) and mouse (HEL30) keratinocytes when examining effects of arsenite that may contribute to the development of cancer. Specifically, this study is designed to evaluate the effect of short-term arsenic exposure on keratinocyte viability under standard culture conditions and examine the ability of arsenite to modulate stress/redox-related gene expression in NHEK and HaCaT and HEL30 keratinocytes. It is proposed that NHEK display increased sensitivity to the gene-modulating effects of arsenite compared with HeLa and HEL30 keratinocytes. The resulting data indicate that arsenite affects cellular viability in NHEK and HaCaT and HEL30 keratinocytes to a similar degree. However, arsenite elevates NHEK stress-related gene expression above that seen in HaCaT and HEL30 keratinocytes. This study will help define the importance of using primary or immortal keratinocytes in experiments designed to elucidate the toxic and carcinogenic mode of action of arsenic in skin, as well as allow for the selection of appropriate in vitro models to evaluate dermatotoxicity.

Materials and Methods

Media and Reagents

Culture media for immortalized keratinocyte cultures. Rich media for mammalian cell culture (RPMI-1640), fetal calf serum (FCS), and L-glutamine were purchased from Life Technologies (Rockville, MD, USA).

Culture media for normal human keratinocytes. Keratinocyte basal medium (KBM-2) and growth supplements were obtained from BioWhittaker/Clonetics (Walkersville, MD, USA). Trypsin–EDTA, penicillin, streptomycin, and neutral red solution were obtained from Life Technologies. Sodium-m arsenite and l-buthionine-[S,R]- sulfoximine (BSO) were obtained from Sigma Chemical Company (St. Louis, MO, USA).

Tissue Culture

Adult NHEK (BioWhittaker/Clonetics) were cultured (passage ≤ 6) in low calcium concentration (0.15 mM) KBM-2 supplemented with epidermal growth factor (5 ng/mL) and bovine pituitary extract (50 mg/mL). The spontaneously immortalized human keratinocyte cell line HaCaT was donated by H. Hamadeh (National Institute of Environmental Health Sciences, Research Triangle Park, NC, USA) and was cultured in RPMI-1640, penicillin 50,000 U/mL, streptomycin 50 mg/L, and penicillin–streptomycin.
10% FCS. Immortalized HEL30 keratinocytes were a gift from E. Corsini (Laboratory of Toxicology, Institute of Pharmacological Sciences, University of Milan, Milan, Italy) and were cultured similar to HaCaT keratinocytes. Cells were incubated at 37°C in a CO₂-enriched atmosphere (5%), and for all experiments, arsenite treatment was carried out at approximately 50–70% confluence and during logarithmic growth.

Cytotoxicity Determination

Keratinocytes were seeded into 96-well plates (2,500 cells/well), grown to approximately 50–70% confluence (2–3 days), and treated with 0, 0.001, 0.003, 0.01, 0.03, 0.1, 0.3, 1, 3, 10, 30, or 100 µM sodium arsenite in KBM-2 without bovine pituitary extract/hydrocortisone (NHEK), or RPMI-1640 (HaCaT and HEL30) (in triplicate). Viability was assessed 24 hr later by incubation with 50 µg/mL neutral red for 3 hr at 37°C. Cells were fixed in formaldehyde/CaCl₂, and dye taken up by viable cells was extracted with ethanol/acetic acid prior to absorbency determination at 570 nm using a microplate reader. Each point represents the mean of three samples. Error bars denote SEM, and asterisk (*) indicates a statistically significant difference (p < 0.05).

Results

Arsenite-induced cytotoxicity was quantified using neutral red uptake in NHEK and HaCaT and HEL30 keratinocytes. Figure 1 shows the median lethal concentration (LC₅₀) for arsenite in NHEK and HEL30 keratinocytes is approximately 10–15 µM after 24-hr exposure, whereas the LC₅₀ for HaCaT keratinocytes is approximately 30 µM. Cytotoxicity measured at 48 hr is similar to that at 24 hr in HEL30 and HEL30 keratinocytes and indicates that arsenite concentrations ≤ 3 µM are nontoxic (data not shown).

Arsenic-induced stress has been examined in keratinocytes; however, arsenite-modulated stress-related gene expression is not well characterized in NHEK. Our laboratory previously determined that NHEK treated with arsenite display alterations in stress/redox-related gene expression (28). Two of these genes, stk25 and nad(p)h quinone oxidoreductase, were chosen to evaluate if physiologically relevant concentrations of arsenite (low and high nontoxic concentrations, 0.005 or 2.5 µM, respectively) regulate stress/redox-related gene expression differentially between NHEK and HaCaT and HEL30 keratinocytes. Figures 2 and 3 are representative Northern blots examining gene expression at time points consistent with arsenite-induced immediate early gene expression, cytokine induction, and effects on cell division. Figure 2A indicates that NHEK nad(p)h quinone oxidoreductase expression is elevated at 24 hr of arsenite exposure (2.5 µM) approximately 3.4-fold but remains near baseline at 4 hr (1.3-fold). Arsenite at the same concentration results in a minimal increase in nad(p)h quinone oxidoreductase expression in HaCaT keratinocytes (1.2-fold at 4 and 24 hr) (Figure 2B), and in HEL30 keratinocytes 1.1- and 1.5-fold changes are observed at 4 and 24 hr, respectively (Figure 2C). Arsenite-induced stress-related gene expression is demonstrated further in Figure 3. Expression of stk25 in NHEK is elevated approximately 2-fold (4 hr) and 2.7-fold (24 hr) at 2.5 µM arsenite (Figure 3A), whereas in HaCaT keratinocytes it remains near baseline at 4 and 24 hr (1.4- and 1.2-fold, respectively) (Figure 3B). Figure 3C

Figure 1. Effect of sodium arsenite on cellular viability in NHEK and HaCaT and HEL30 keratinocytes. Cells were seeded into 96-well plates (2,500 cells/well) and grown to approximately 50% confluence. The indicated concentrations of sodium arsenite were added in triplicate and cells were allowed to incubate for 24 hr. Medium containing arsenite was then removed and replaced with fresh medium containing neutral red (50 µg/mL) for 3 hr. The cells were fixed, neutral red was extracted, and dye absorbency was quantified at 570 nm using a microplate reader. Each point represents the mean of three samples. Error bars denote SEM, and asterisk (*) indicates a statistically significant difference (p < 0.05) from control (no arsenite) as determined by ANOVA. Data are representative of an experiment replicated a minimum of 3 times.
reveals that in HEL30 keratinocytes there is no change in stk25 expression at 24 hr and a slight reduction at 4 hr (0.9-fold) after exposure to 2.5 µM arsenite.

GSH attenuates the damaging effects of arsenite in numerous biological systems \((26,29,30)\), and reduction in cellular GSH exacerbates cellular responses to redox-regulating agents \((31,32)\) and arsenic \((33,34)\).

Figure 4 demonstrates that the addition of 100 µM BSO to culture medium shifts the LC₅₀ of arsenite 10-fold to approximately 1 µM in NHEK, suggesting that a reduction in GSH increases the potency of arsenite. Similar effects were observed in HaCaT and HEL30 keratinocytes (data not shown). BSO has no effect on NHEK viability at arsenite concentrations ≤0.3 µM, suggesting that low concentrations of arsenite do not produce cytotoxicity under conditions where the level of cellular GSH is compromised. To determine if a reduction in GSH influences arsenite-induced nad(p)h quinone oxidoreductase and stk25 expression, NHEK were exposed to 0.005 or 2.5 µM arsenite and BSO as described in “Materials and Methods.” Data in Figure 5 indicate that BSO treatment does not result in the induction of nad(p)h quinone oxidoreductase or stk25 expression at 0.005 µM arsenite. However, Figure 5A shows that the gene-inducing effect of 2.5 µM arsenite is attenuated when used in combination with BSO, resulting in a 0.4- and 2.6-fold change in nad(p)h quinone oxidoreductase expression at 4 and 24 hr, respectively. (Compare with 1.3- and 3.4-fold from control NHEK, cross-hatched bars.) Figure 5B reveals that stk25 induction at 2.5 µM arsenite also is attenuated after BSO treatment (1.4- and 1.8-fold at 4 and 24 hr, respectively; compare with 2- and 2.7-fold from control NHEK, cross-hatched bars).

**Discussion**

NHEK and HaCaT and HEL30 keratinocytes are epidermal cells used to characterize the effects of arsenic on proliferative gene expression \((5,39)\), cytokine and growth factor expression \((6,8,36)\), and the role reactive oxygen species (ROS) play in epidermal dysfunction and signal transduction modulation \((37-39)\). Although well suited with respect to target tissue, these cells present unique phenotypes that may display different responses to oxidative stress-inducing agents like arsenic. NHEK are resistant to transformation when grown under normal conditions in vitro, have a finite lifespan, and retain many physiological characteristics observed in vivo (e.g., differentiation response) \((40)\). The human HaCaT cell line displays a transformed phenotype in vitro but remains non-tumorigenic \((41)\). Despite an unlimited growth potential, HaCaTs, similar to normal...
human keratinocytes, can form a structured and differentiated architecture when transplanted into nude mice, and they also express differentiation-specific keratins and other markers (e.g., involucrin and filaggrin) (41). The HEL30 cell line is derived from the spontaneous transformation of murine keratinocytes grown in vitro (42–46) and is tumorigenic and invasive (47).

Arsenic is cytotoxic to normal human keratinocytes (35), fibroblasts (48,49), lymphocytes (50), hepatocytes (51), and epidermoid carcinoma cells (52). In a majority of these studies, short-term exposure to trivalent arsenicals results in significant cytotoxicity at concentrations between 1 and 10 µM. In our study, arsenite-induced cytotoxicity was dose dependent and resulted in a short-term LC50 of approximately 10–15 µM in NHEK and HEL30 keratinocytes and 30 µM in HaCaT keratinocytes. NHEK and HEL30 keratinocytes present a similar sensitivity toward arsenite-induced cytotoxicity that is hard to resolve because rodent cells generally have increased antioxidant capabilities compared with human cells (49,53). HaCaT keratinocytes display alterations in antioxidant enzyme levels (54), and this may partially explain the increased LC50 for arsenite in this cell type.

We chose to examine the expression of two genes regulated by extra and intracellular stress (e.g., stk25 and nad(p)h quinone oxidoreductase) at two nontoxic concentrations of arsenite (0.005 and 2.5 µM). Ste20-homologous proteins (e.g., STK25) are implicated as important transducers of signals from the p21 family of GTPases (55,56), can be activated by cellular stress, and are important mediators of oxidant-mediated signal transduction (57,58). In this study arsenite robustly induced NHEK stk25 expression, an effect more profound in primary cells, and an effect attenuated by reducing GSH level with BSO. Whether the ability of NHEK to respond so robustly compared with HaCaT or HEL30 keratinocytes is a detoxification mechanism preserved in primary cells or a prelude to immortalization is unknown at present. However, the elevated baseline stk25 expression observed in HaCaT and HEL30 keratinocytes would support the notion that this alteration is associated with immortalization. Along with previously defined effects of arsenic on mitogen and stress-related signal transduction (7,10,16,33,59), these data implicate STK25 in the transduction of arsenite-mediated stress signals.

NAD(P)H quinone oxidoreductase is a flavoprotein that catalyzes the reduction of quinones, quinone imines, and azo dyes, thereby protecting cells against free radical and ROS-mediated mutagenicity and carcinogenicity (60–62). Elevated NAD(P)H quinone oxidoreductase activity and gene expression are observed in both preneoplastic tissues and established tumors (63,64) and are induced by a variety of compounds including planar aromatic hydrocarbons, phenolic antioxidants, tumor promoters, and hydrogen peroxide (61). In our study, nad(p)h quinone oxidoreductase expression was dramatically increased in NHEK after exposure to a nontoxic concentration of arsenite (approximately 4-fold at 2.5 µM) compared with HaCaT and HEL30 keratinocytes. Interestingly, a similar trend in baseline and arsenite-induced nad(p)h quinone oxidoreductase expression in both HaCaT and HEL30 keratinocytes was observed, suggesting an immortalization/preneoplastic effect on gene expression. The mechanism(s) involved in

---

**Figure 4.** Effect of BSO on arsenite-induced cytotoxicity in NHEK. Cells were prepared as in Figure 1 with the exception that BSO (100 µM) in fresh culture medium was added to cells 24 hr prior to arsenite treatment. After removal of medium, the indicated concentrations of arsenite in fresh medium containing BSO (100 µM) were added to triplicate wells, and cells were allowed to incubate for an additional 24 hr. Cellular viability was determined as in Figure 1. Each point represents the mean of three samples. Error bars denote SEM, and asterisk (*) indicates a statistically significant difference (p < 0.05) from control (no arsenite) as determined by ANOVA. Data are representative of an experiment replicated a minimum of 3 times.

**Figure 5.** Effect of BSO treatment on arsenite-induced nad(p)h quinone oxidoreductase and stk25 expression in NHEK. Northern blot analysis of 10 µg total RNA from NHEK pretreated with 100 µM BSO for 24 hr, exposed to arsenite for 4 or 24 hr, and probed for nad(p)h quinone oxidoreductase or stk25. Band intensity was digitized using Image Quant software (Molecular Dynamics). (A) nad(p)h quinone oxidoreductase (1B) stk25. RNA bands (28S and 18S) from an ethidium bromide–stained gel indicate equivalent loading of RNA. Bar graphs indicate percent increase above time-matched control (0 µM arsenite). Black bars = BSO-treated NHEK and cross-hatched bars = data from control NHEK presented previously in Figures 2A and 3A.
arsenite-mediated nad(p)h quinone oxidoreductase induction in NHEK is currently unknown. However, oxidative stress activates activator protein-1 (AP-1) in human keratinocytes and other cells (65,66) and may contribute to elevated nad(p)h quinone oxidoreductase in human keratinocytes. Toxicol Appl Pharmacol 141(1):308–318 (1996).

7. Yen HT, Chang LC, Wen KH, Chang SF, Tsai CC, Yu CL, Yu HS. Arsenic induces interleukin-8 expression in cultured keratinocytes. Arch Dermatol Res 288(11):716–717 (1996).

8. Luster MJ, Wilmer JL, Gemelko DR, Spalding, J, Yoshida T, Gaido K, Simonova PP, Burleson FG, Bruccoleri A. Role of keratinocyte growth factors in chemical toxicity. Toxicol Lett 82:473–477 (1995).

9. Chen H, Liu J, Zhao QG, Diwan BA, Merrick BA, Waalkes MP. Association of c-myc overexpression and hyperproliferation with arsenic-induced malignant transformation. Toxicol Appl Pharmacol 175(3):260–268 (2001).

10. Chen H, Liu J, Merrick BA, Waalkes MP. Genetic events associated with arsenic-mediated malignant transformation: applications of DNA microarray technology. Mal Cancer 20(2):79–87 (2001).

11. Mass MJ, Wang L. Arsenic alters cytokine methylation patterns of the promoter of the tumor suppressor gene p53 in human lung cells: a model for a mechanism of carcinogenesis. Mutat Res 383(3-4):263–277 (1997).

12. Vogt BL, Rossman TG. Effects of arsenic on p53, p21 and cyclin D expression in normal human fibroblasts—a possible mechanism for arsenic’s comutagenicity. Mutat Res 4781(1-2):155–169 (2000).

13. Rassmann TG, Udrika BN, Burns FJ, Bosland MC. Arsenite is a cocarcinogen with solar ultraviolet radiation for mouse skin: an animal model for arsenic carcinogenesis. Toxicol Appl Pharmacol 176(1):84–91 (2001).

14. Duoluo FN, Grillo CI, Medenina CR, Nilsson R, Vaher M, Darroudi F, Natarajan AT. Chromosomal aberrations in peripheral blood lymphocytes from native Andean women and children from Northwestern Argentina exposed to arsenic in drinking water. Mutat Res 270(3-4):151–158 (1996).

15. Trubova KJ, Wauson EM, Vorce RL. Sodium arsenite-induced dysregulation of proteins involved in proliferative cell signaling. Toxicol Appl Pharmacol 164(2):161–170 (2000).

16. Matsui M, Nishigori C, Toyokuni S, Takada J, Akasobi M, Ishikawa M, Inamura S, Miyachi Y. The role of oxidative DNA damage in human arsenic carcinogenesis: detection of 8-hydroxy-2′-deoxyguanosine in arsenic-related Bowen’s disease. J Invest Dermatol 113(2):26–31 (1999).

17. Buzard GS, Kasprzak KS. Possible role of nitric oxide and redox signaling in metal-induced toxicity and carcinogenesis: a review. J Environ Pathol Toxicol Oncol 19(3):179–199 (2000).

18. Yamanaka K, Miyazawa M, Kato K, Hasegawa A, Nakano M, Okada S. Oral administration of dimethylylarsinic acid, a main metabolite of inorganic arsenic, in mice promotes skin tumorigenesis induced by dimethylbenz(a)anthracene with or without B as a promoter. Biol Pharm Bull 24(5):510–514 (2001).

19. Pott WA, Benjamin SA, Yang RS. Pharmacokinetics, metabolism, and mechanistic aspects of arsenic. Environ Health Perspect 109(8):886–891 (1997).

20. Gschwendt M, Kittstein W, Marks F. Cyclosporin A inhibits redox modulation of cellular antioxidant defense and metal-induced toxicity in a human keratinocyte cell line. Mutat Res 153(1):175–179 (1988).

21. Barchowsky A, Klei LR, Dudek EJ, Swartz HM, James PE. Coordination of altered DNA repair and damage pathways in arsenic exposed keratinocytes. Toxicol Sci (in press).

22. Occhi T, Kaise T, Dya-Ohta Y. Glutathione plays different roles in the induction of the cytotoxic effects of inorganic and organic arsenic compounds in culture BALB/c 3T3 cells. Exp Cell Res 502(1):113–120 (1994).

23. Chang WC, Chen SH, Wu H, Shi GY, Murata S, Morita I. Cytoprotective effect of reduced glutathione in arsenical-induced endothelial cell injury. Toxicology 98(1):101–110 (1991).

24. Oguro T, Hayashi M, Numazawa S, Asakawa K, Yoshida T. Human oxygenase-1 gene expression induced by a glutatione dependent, phosphor, mediated through AP-1 activation in rats. Biochem Biophys Res Commun 221(2):259–265 (1995).

25. Tanaka C, Kamata H, Takeshita H, Yagisawa H, Hirata H. Redox regulation of lipopolysaccharide (LPS)-induced interleukin-8 (IL-8) gene expression mediated by NF-kappa B and AP-1 in human aortic smooth muscle cells. Mol Pharmacol 51(2):573–579 (1997).

26. Shimizu M, Hochadel JF, Fulmer BA, Waalkes MP. Effect of glutathione depletion and metallothionein gene expression on arsenic-induced cytotoxicity and c-myc expression in vitro. Toxicol Sci 45(2):204–211 (1998).

27. Dya-Ohta Y, Kaise T, Occhi T. Induction of chromosomal aberrations in cultured human fibroblasts by inorganic and organic arsenic compounds and the different roles of glutathione in such induction. Mut Res 357(1-2):121–129 (1996).

28. Dees BS, Dennings C, Carter WH Jr, Yang RS, Campbell PA. Toxicological interactions among arsenic, cadmium, chromium, and lead in human keratinocytes. Toxicol Sci 63(1):132–142 (2001).

29. Gemelko DR, Spalding J, Yu HS, Chen GS, Simonova PP, Humble MC, Bruccoleri A, Boorman GA, Foley JE, Yoshida T, et al. Arsenic enhancement of skin neoplasia by chronic stimulation of growth factors. Am J Pathol 153(6):1755–1765 (1998).

30. Goldman R, Moshonov S, Zor U. Generation of reactive oxygen species in a human keratinocyte cell line: role of calcium. Arch Biochem Biophys 350(1):18–24 (1998).

31. Assefa Z, Garmyn M, Bouillon R, Merlevede W, Vandeneerde JR, Agostinis P. Differential stimulation of ERK and JNK activities by ultraviolet B irradiation and epidermal growth factor in human keratinocytes. J Invest Dermatol 108(4):886–891 (1997).

32. Giudicetti R, Thorn T, Vicanova J, Petersen A, Wulf HC. Role of mitochondria in ultraviolet-induced oxidative stress. J Cell Biochem 82(2):216–222 (2000).

33. Thraoves P, Salehi Z, Ditschko A, Rhim JS. Neoplastic transformation of immortalized human epithelial keratinocytes by ionizing radiation. Proc Natl Acad Sci USA 87(3):1174–1177 (1990).

34. Boukamp P, Petrussevska RT, Breitkreutz D, Hornung J, Markham A, Fuesing NE. Normal keratinization in a spontaneously immortalized aneuploid human keratinocyte cell line. J Cell Biol 106(3):761–771 (1988).

35. Corsini E, Mariniovic M, Galli CL. In vitro keratinocytes responses to chemical allergens. Biol Chem 340(10):569–572 (1995).

36. Corsini E, Schubert C, Mariniovic M, Galli CL. Role of mitochondria in tributyltin-induced interleukin-1alpha production in murine keratinocytes. J Invest Dermatol 107(5):720–725 (1996).

37. Marks F, Banke B, Thastrop D, Furnerberger G. Stimulatory effect of thapsigargin, a non-TPA-type tumor promoter, on arachidonic acid production in the murine keratinocyte line HEL30 and on epithelial cell proliferation in vivo as compared to the effects of phorbol ester TPA. Carcinogenesis 19(12):3045–3050 (1998).

38. Gschwendt M, Kretinin W, Marks F. Cyclosporin A inhibits phorbol ester-induced cellular proliferation and tumor promotion as well as phosphorylation of a 100-kD protein kinase in mouse epidermis. Carcinogenesis 18(3):519–523 (1997).

39. Seemann D, Furnerberger G, Marks F. Effects of the skin mitogens tumor-promoter 12-0-Tetradecanoylphorbol 13-acetate and divalent-cation-ionophore A23187 on ion fluxes and membrane potential in the murine keratinocyte line HEL30 and in 3T3 fibroblasts. Eur J Biochem 137(3):485–494 (1983).

40. Houghton J, Bohnten A, Phan-Than L, Krieg T, Fuesing NE. Basement membrane formation by malignant mouse keratinocyte cell lines in organotypic culture and transplants: correlation with degree of morphological differentiation. J Invest Dermatol 113(4):225–234 (1999).

41. Trubova KJ, Glanzer JG, Vorce RL. Wild-type and...
Ras-transformed fibroblasts display differential mitogenic responses to transient arsenite exposure. Toxicol Sci 50(1):72–81 (1999).

50. Rosman TG, Goncharova EI, Rajah T, Wang Z. Human cells lack the inducible tolerance to arsenite seen in hamster fibroblasts and Chinese hamster ovary (1996).

51. Huang RN, Lee TC. Cellular uptake of trivalent arsenite and bioavailable pentavalent arsenate in KB cells cultured in phosphate-free medium. Toxicol Appl Pharmacol 136(2):243–249 (1997).

52. Huang RN, Lee TC. Differential cytotoxicity of sodium arsenite and more toxic than arsenite in Chang human hepatocytes. Toxicol Appl Pharmacol 163(2):203–207 (2000).

53. Rossman TG, Goncharova EI, Rajah T, Wang Z. Human cells lack the inducible tolerance to arsenite seen in Chang human hepatocytes. Toxicol Appl Pharmacol 163(2):203–207 (2000).

54. Leccia MT, Richard MJ, Joanny-Crisci F, Beani JC. UV-A1 fibroblasts and stimulated human lymphocytes. Teratog Carcinog Mutagen 21(4):249–260 (2001).

55. Brown JL, Stowers L, Baer M, Trejo J, Coughlin S, Chant J. Actions of Rho family small G proteins and p21-activated kinase-1 during the initial stages of chemical anoxia-induced necrotic cell death. Requirement for dual inputs of oxidant stress and increased cytosolic [Ca2+]. J Biol Chem 272(48):29372–29379 (1997).

56. Frost JA, Ayala-Fierro F, Cullen WR, Carter DE, Vasken Sordo M, Herrera LA, Ostrosky-Wegman P, Rojas E. Arsenic induces oxidant stress and NF-κB activation in cultured aortic endothelial cells. Biochem Pharmacol 42(5):1021–1027 (1991).

57. Pombo CM, Tsujita T, Kyriakis JM, Bonventre JV, Force T. Activation of the Ste20-like kinase by oxidant stress defines a novel stress response pathway. Embo J 15(17):4537–4546 (1996).

58. Pombo CM, Bonventre JV, Molnar A, Kyriakis J, Force T. Activation of a human Ste20-like kinase by oxidant stress defines a novel stress response pathway. Embo J 15(17):4537–4546 (1996).

59. Jaiswal AK. Jun and Fos regulation of NAD(P)H: quinone oxidoreductase1 (DT-diaphorase) specifically prevents the formation of benzo[a]pyrene quinone-DNA adducts generated by cytochrome P4501A1 and P450 reductase. Proc Natl Acad Sci USA 91(18):8413–8417 (1994).

60. Joseph P, Jaiswal AK. NAD(P)H: quinone oxidoreductase1 (DT-diaphorase): expression, regulation, and role in cancer. Oncol Res 6(10-11):525-32 (1994).

61. Joseph P, Xie T, Xu Y, Jaiswal AK. NAD(P)H:quinone oxidoreductase1 (DT-diaphorase): expression, regulation, and role in cancer. Oncol Res 6(10-11):525-32 (1994).

62. Jaiswal AK. Jun and Fos regulation of NAD(P)H: quinone oxidoreductase gene expression. Pharmacogenetics 4(1):1–10 (1994).

63. Cresteil T, Jaiswal AK. High levels of expression of the NAD(P)H:quinone oxidoreductase (NOQ1) gene in tumor cells compared to normal cells of the same origin. Biochem Pharmacol 42(5):1021–1027 (1991).

64. Schlager JJ, Pospisil S. Cytoxic NAD(P)H:quinone-acceptor oxidoreductase in human normal and tumor tissue: effects of cigarette smoking and alcohol. Int J Cancer 45(3):403–409 (1990).

65. Burleson FG, Simeonova PP, Germolec DR, Luster MI. Dermatoxic chemical stimulate of c-jun and c-fos transcription and AP-1 DNA binding in human keratinocytes. Res Commun Mol Pathol Pharmacol 93(2):131–148 (1996).

66. Simeonova PP, Wang S, Toriumi W, Kommineni V, Matheson J, Unimye N, Kayama F, Hariki D, Ding M, Vallyathan V, et al. Arsenic mediates cell proliferation and gene expression in the bladder epithelium: association with activating protein-1 transactivation. Cancer Res 60(13):3445–3453 (2000).

67. Burleson FG, Simeonova PP, Germolec DR, Luster MI. Dermatoxic chemical stimulate of c-jun and c-fos transcription and AP-1 DNA binding in human keratinocytes. Res Commun Mol Pathol Pharmacol 93(2):131–148 (1996).

68. Parrish AR, Zheng MX, Turney KD, Younis HS, Gandolfi AJ. Enhanced transcription factor DNA binding and gene expression induced by arsenite or arsenate in renal slices. Toxicol Sci 50(1):98–105 (1999).

69. Burleson FG, Simeonova PP, Germolec DR, Luster MI. Dermatoxic chemical stimulate of c-jun and c-fos transcription and AP-1 DNA binding in human keratinocytes. Res Commun Mol Pathol Pharmacol 93(2):131–148 (1996).

70. Barchowsky A, Dudek EJ, Treadwell MD, Wetterhahn KE. Arsenic induces oxidant stress and NF-kappa B activation in cultured aortic endothelial cells. Free Radic Biol Med 21(6):783–790 (1996).

71. Roussel RR, Barchowsky A. Arsenic inhibits NF-kappaB-mediated gene transcription by blocking IkappaB kinase activity and IkappaBalpha phosphorylation and degradation. Arch Biochem Biophys 371(2):204–212 (2000).

72. Bergelson S, Pinkus R, Daniel V. Intracellular glutathione levels regulate Fos/Jun induction and activation of glutathione S-transferase gene expression. Cancer Res 54(1):36–40 (1994).